{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:59:06Z","timestamp":1775757546013,"version":"3.50.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-018944"],"award-info":[{"award-number":["INV-018944"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe Covid-19 leads to higher neutralizing antibody levels, a key correlate of protection. However, the host proteins associated with this response have not been fully characterized. We asked which proteins in the blood plasma associate with neutralization, anti-spike antibody levels, and disease severity in a South African cohort upon first SARS-CoV-2 exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a longitudinal observational cohort design to collect blood at 6 days (acute infection) and 32 days (convalescence) post-diagnosis. We performed SomaScan proteomics on acute blood plasma and measured SARS-CoV-2 plasma neutralization capacity and anti-spike antibody levels in convalescent plasma. Disease severity was scored based on requirement for supplemental oxygen and was mild to moderate (no critically ill participants).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We find differentially expressed proteins associating with neutralization, anti-spike antibody levels, and disease severity, with strong overlap between proteins associated with\u00a0neutralization and spike binding, and moderate overlap between neutralization and disease severity. High neutralizers, regardless of requirement for supplemental oxygen, are found to have risk factors and markers for being more ill compared to low neutralizers. We can reasonably predict who becomes a high neutralizer based on individual proteins. The best predictor for neutralization is HSPA8, known to bind viral proteins and cross-present extracellular antigens. The strongest associated pathway is fatty acid metabolism, whose inhibition results in suppression of viral replication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results show that host proteins and pathways involved early in SARS-CoV-2 infection associate with neutralizing antibody levels elicited by the infection at convalescence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01427-7","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:16:48Z","timestamp":1770967008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-7032","authenticated-orcid":false,"given":"Afrah","family":"Khairallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zesuliwe","family":"Jule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0158-3637","authenticated-orcid":false,"given":"Alice","family":"Piller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-2391","authenticated-orcid":false,"given":"Mallory","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kajal","family":"Reedoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yashica","family":"Ganga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sashkia R.","family":"Balla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prudence","family":"Kgagudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7489","authenticated-orcid":false,"given":"Bernadett I.","family":"Gosnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farina","family":"Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6191-4023","authenticated-orcid":false,"given":"Mahomed-Yunus S.","family":"Moosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-3992","authenticated-orcid":false,"given":"Thumbi","family":"Ndung\u2019u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thandeka","family":"Moyo-Gwete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-4028","authenticated-orcid":false,"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-7400","authenticated-orcid":false,"given":"Khadija","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-2004","authenticated-orcid":false,"given":"Alex","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"1427_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"1427_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4947","volume":"376","author":"JRC Pulliam","year":"2022","unstructured":"Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 376, eabn4947 (2022).","journal-title":"Science"},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"1427_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37176-7","volume":"14","author":"D Cromer","year":"2023","unstructured":"Cromer, D. et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nat. Commun. 14, 1633 (2023).","journal-title":"Nat. Commun."},{"key":"1427_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"1427_CR9","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","volume":"184","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332\u20132347.e2316 (2021).","journal-title":"Cell"},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","volume":"184","author":"A Sokal","year":"2021","unstructured":"Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201\u20131213.e1214 (2021).","journal-title":"Cell"},{"key":"1427_CR12","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","volume":"54","author":"F Muecksch","year":"2021","unstructured":"Muecksch, F. et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54, 1853\u20131868.e1857 (2021).","journal-title":"Immunity"},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184, 476\u2013488.e411 (2021).","journal-title":"Cell"},{"key":"1427_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","volume":"27","author":"C Lucas","year":"2021","unstructured":"Lucas, C. et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat. Med. 27, 1178\u20131186 (2021).","journal-title":"Nat. Med."},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","volume":"5","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal. Transduct. Target. Ther. 5, 180 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1427_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81862-9","volume":"11","author":"B Trinit\u00e9","year":"2021","unstructured":"Trinit\u00e9, B. et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci. Rep. 11, 2608 (2021).","journal-title":"Sci. Rep."},{"key":"1427_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20247-4","volume":"12","author":"EHY Lau","year":"2021","unstructured":"Lau, E. H. Y. et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat. Commun. 12, 63 (2021).","journal-title":"Nat. Commun."},{"key":"1427_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598\u20131607 (2020).","journal-title":"Nat. Microbiol."},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41423-020-00588-2","volume":"18","author":"V Legros","year":"2021","unstructured":"Legros, V. et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell. Mol. Immunol. 18, 318\u2013327 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"1427_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.628971","volume":"11","author":"S Schlickeiser","year":"2020","unstructured":"Schlickeiser, S. et al. Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses. Front. Immunol. 11, 628971 (2020).","journal-title":"Front. Immunol."},{"key":"1427_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41392-021-00611-6","volume":"6","author":"X Xu","year":"2021","unstructured":"Xu, X. et al. Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study. Signal Transduct. Target. Ther. 6, 197 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1427_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17605-1","volume":"12","author":"Y Kim","year":"2022","unstructured":"Kim, Y. et al. Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity. Sci. Rep. 12, 13491 (2022).","journal-title":"Sci. Rep."},{"key":"1427_CR23","doi-asserted-by":"publisher","unstructured":"Boonyaratanakornkit, J. et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. J. Clin. Investig. 131 https:\/\/doi.org\/10.1172\/jci144930 (2021).","DOI":"10.1172\/jci144930"},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1172\/JCI142004","volume":"130","author":"SL Klein","year":"2020","unstructured":"Klein, S. L. et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J. Clin. Investig. 130, 6141\u20136150 (2020).","journal-title":"J. Clin. Investig."},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","volume":"20","author":"MM Lamers","year":"2022","unstructured":"Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 20, 270\u2013284 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417\u20131418 (2020).","journal-title":"Lancet"},{"key":"1427_CR27","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s11606-022-07511-7","volume":"37","author":"M Rubio-Rivas","year":"2022","unstructured":"Rubio-Rivas, M. et al. WHO ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales. J. Gen. Intern Med. 37, 1980\u20131987 (2022).","journal-title":"J. Gen. Intern Med."},{"key":"1427_CR28","doi-asserted-by":"publisher","unstructured":"Karim, F. et al. HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. Elife 10 https:\/\/doi.org\/10.7554\/eLife.67397 (2021).","DOI":"10.7554\/eLife.67397"},{"key":"1427_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03374-8","volume":"24","author":"X Li","year":"2020","unstructured":"Li, X. et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit. Care 24, 647 (2020).","journal-title":"Crit. Care"},{"key":"1427_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-37606-y","volume":"13","author":"C Prebensen","year":"2023","unstructured":"Prebensen, C. et al. Longitudinal whole blood transcriptomic analysis characterizes neutrophil activation and interferon signaling in moderate and severe COVID-19. Sci. Rep. 13, 10368 (2023).","journal-title":"Sci. Rep."},{"key":"1427_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/cid\/ciaa248","volume":"71","author":"C Qin","year":"2020","unstructured":"Qin, C. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71, 762\u2013768 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1427_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal. Transduct. Target. Ther. 5, 33 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1427_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02374-0","volume":"18","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J. Transl. Med. 18, 206 (2020).","journal-title":"J. Transl. Med."},{"key":"1427_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"1427_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-020-00453-4","volume":"8","author":"I Huang","year":"2020","unstructured":"Huang, I. & Pranata, R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J. Intensive Care 8, 36 (2020).","journal-title":"J. Intensive Care"},{"key":"1427_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01718-3","volume":"22","author":"S Shouman","year":"2024","unstructured":"Shouman, S. et al. SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147. Cell Commun. Signal. 22, 349 (2024).","journal-title":"Cell Commun. Signal."},{"key":"1427_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/20587392211036825","volume":"19","author":"Z-y Zou","year":"2021","unstructured":"Zou, Z. -y. et al. Persistent lymphopenia after diagnosis of COVID-19 predicts acute respiratory distress syndrome: a retrospective cohort study. Eur. J. Inflamm. 19, 20587392211036825 (2021).","journal-title":"Eur. J. Inflamm."},{"key":"1427_CR38","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","volume":"73","author":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, S. A.","year":"2021","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, S. A. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin. Infect. Dis. 73, e2005\u2013e2015 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1427_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41586-022-04830-x","volume":"607","author":"K Khan","year":"2022","unstructured":"Khan, K. et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature 607, 356\u2013359 (2022).","journal-title":"Nature"},{"key":"1427_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","volume":"399","author":"LG Bekker","year":"2022","unstructured":"Bekker, L. G. et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet 399, 1141\u20131153 (2022).","journal-title":"Lancet"},{"key":"1427_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25191-5","volume":"12","author":"M Perreau","year":"2021","unstructured":"Perreau, M. et al. The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nat. Commun. 12, 4888 (2021).","journal-title":"Nat. Commun."},{"key":"1427_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44986-w","volume":"15","author":"E Duijvelaar","year":"2024","unstructured":"Duijvelaar, E., Gisby, J., Peters, J. E., Bogaard, H. J. & Aman, J. Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients. Nat. Commun. 15, 744 (2024).","journal-title":"Nat. Commun."},{"key":"1427_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100287","volume":"2","author":"MR Filbin","year":"2021","unstructured":"Filbin, M. R. et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep. Med. 2, 100287 (2021).","journal-title":"Cell Rep. Med."},{"key":"1427_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106408","volume":"26","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer\u2019s and coronary disease pathways. iScience 26, 106408 (2023).","journal-title":"iScience"},{"key":"1427_CR45","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.4161\/auto.26448","volume":"9","author":"F Stricher","year":"2013","unstructured":"Stricher, F., Macri, C., Ruff, M. & Muller, S. HSPA8\/HSC70 chaperone protein. Autophagy 9, 1937\u20131954 (2013).","journal-title":"Autophagy"},{"key":"1427_CR46","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.4049\/jimmunol.163.4.1936","volume":"163","author":"N Panjwani","year":"1999","unstructured":"Panjwani, N., Akbari, O., Garcia, S., Brazil, M. & Stockinger, B. The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. J. Immunol. 163, 1936\u20131942 (1999).","journal-title":"J. Immunol."},{"key":"1427_CR47","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.immunol.20.100301.064801","volume":"20","author":"P Srivastava","year":"2002","unstructured":"Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20, 395\u2013425 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"1427_CR48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","volume":"30","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30, 154\u2013162.e155 (2022).","journal-title":"Cell Host Microbe"},{"key":"1427_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41579-024-01125-y","volume":"23","author":"A Sigal","year":"2025","unstructured":"Sigal, A., Neher, R. A. & Lessells, R. J. The consequences of SARS-CoV-2 within-host persistence. Nat. Rev. Microbiol. 23, 288\u2013302 (2025).","journal-title":"Nat. Rev. Microbiol."},{"key":"1427_CR50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1525-1497.1998.00031.x","volume":"13","author":"AC Jung","year":"1998","unstructured":"Jung, A. C. & Paauw, D. S. Diagnosing HIV-related disease: using the CD4 count as a guide. J. Gen. Intern Med. 13, 131\u2013136 (1998).","journal-title":"J. Gen. Intern Med."},{"key":"1427_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46673-2","volume":"15","author":"F Karim","year":"2024","unstructured":"Karim, F. et al. Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation. Nat. Commun. 15, 2360 (2024).","journal-title":"Nat. Commun."},{"key":"1427_CR52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele, S. et al. Network for Genomic Surveillance in South, A., Team, C.-K., Lessells, R. J., de Oliveira, T. & Sigal, A. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142\u2013146 (2021).","journal-title":"Nature"},{"key":"1427_CR53","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"1427_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89940-y","volume":"15","author":"JN Bhiman","year":"2025","unstructured":"Bhiman, J. N. et al. Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern. Sci. Rep. 15, 5549 (2025).","journal-title":"Sci. Rep."},{"key":"1427_CR55","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/S2352-3018(18)30104-8","volume":"5","author":"ABM Kharsany","year":"2018","unstructured":"Kharsany, A. B. M. et al. Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey. Lancet HIV 5, e427\u2013e437 (2018).","journal-title":"Lancet HIV"},{"key":"1427_CR56","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430\u2013436 (2020).","journal-title":"Nature"},{"key":"1427_CR57","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2352-3018(16)30216-8","volume":"4","author":"J O\u2019Connor","year":"2017","unstructured":"O\u2019Connor, J. et al. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per \u03bcL: secondary outcome results from a randomised controlled trial. Lancet HIV 4, e105\u2013e112 (2017).","journal-title":"Lancet HIV"},{"key":"1427_CR58","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","volume":"360","author":"MM Kitahata","year":"2009","unstructured":"Kitahata, M. M. et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med. 360, 1815\u20131826 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1427_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19996-z","volume":"11","author":"M Pietzner","year":"2020","unstructured":"Pietzner, M. et al. Genetic architecture of host proteins involved in SARS-CoV-2 infection. Nat. Commun. 11, 6397 (2020).","journal-title":"Nat. Commun."},{"key":"1427_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94256-8","volume":"11","author":"J Yang","year":"2021","unstructured":"Yang, J. et al. Proteomics and metabonomics analyses of Covid-19 complications in patients with pulmonary fibrosis. Sci. Rep. 11, 14601 (2021).","journal-title":"Sci. Rep."},{"key":"1427_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ebiom.2018.12.048","volume":"40","author":"J Dunn","year":"2019","unstructured":"Dunn, J. et al. Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine 40, 77\u201391 (2019).","journal-title":"EBioMedicine"},{"key":"1427_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25202-5","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting. Nat. Commun. 12, 4961 (2021).","journal-title":"Nat. Commun."},{"key":"1427_CR63","doi-asserted-by":"publisher","unstructured":"Navhaya, L. T., Blessing, D. M., Yamkela, M., Godlo, S. & Makhoba, X. H. A comprehensive review of the interaction between COVID-19 spike proteins with mammalian small and major heat shock proteins. Biomol. Concepts 15 https:\/\/doi.org\/10.1515\/bmc-2022-0027 (2024).","DOI":"10.1515\/bmc-2022-0027"},{"key":"1427_CR64","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1016\/j.febslet.2006.09.040","volume":"580","author":"K Watanabe","year":"2006","unstructured":"Watanabe, K. et al. Identification of Hsc70 as an influenza virus matrix protein (M1) binding factor involved in the virus life cycle. FEBS Lett. 580, 5785\u20135790 (2006).","journal-title":"FEBS Lett."},{"key":"1427_CR65","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1128\/JVI.78.11.5546-5553.2004","volume":"78","author":"L Florin","year":"2004","unstructured":"Florin, L. et al. Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. J. Virol. 78, 5546\u20135553 (2004).","journal-title":"J. Virol."},{"key":"1427_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","volume":"591","author":"BA Johnson","year":"2021","unstructured":"Johnson, B. A. et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591, 293\u2013299 (2021).","journal-title":"Nature"},{"key":"1427_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/path.2343","volume":"215","author":"BE Needham","year":"2008","unstructured":"Needham, B. E. et al. Identification of the Alzheimer\u2019s disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J. Pathol. 215, 155\u2013163 (2008).","journal-title":"J. Pathol."},{"key":"1427_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02692-z","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Amyloid precursor protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid-\u03b2-associated pathology in APP\/PS1 mouse model of Alzheimer\u2019s disease. Transl. Psychiatry 13, 396 (2023).","journal-title":"Transl. Psychiatry"},{"key":"1427_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.754490","volume":"8","author":"LS Bisgaard","year":"2021","unstructured":"Bisgaard, L. S. & Christoffersen, C. The apoM\/S1P complex-A mediator in kidney biology and disease?. Front Med (Lausanne) 8, 754490 (2021).","journal-title":"Front Med (Lausanne)"},{"key":"1427_CR70","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3390\/biom13121718","volume":"13","author":"N Basalova","year":"2023","unstructured":"Basalova, N., Alexandrushkina, N., Grigorieva, O., Kulebyakina, M. & Efimenko, A. Fibroblast activation protein alpha (FAP\u03b1) in fibrosis: beyond a perspective marker for activated stromal cells?. Biomolecules 13, 1718 (2023).","journal-title":"Biomolecules"},{"key":"1427_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41392-020-00233-4","volume":"5","author":"Q Wan","year":"2020","unstructured":"Wan, Q., Song, D., Li, H. & He, M. -l Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development. Signal Transduct. Target. Ther. 5, 125 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1427_CR72","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1038\/onc.2012.514","volume":"32","author":"HY Tsai","year":"2013","unstructured":"Tsai, H. Y. et al. Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. Oncogene 32, 4921\u20134931 (2013).","journal-title":"Oncogene"},{"key":"1427_CR73","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14728222.12.2.159","volume":"12","author":"I Gravanis","year":"2008","unstructured":"Gravanis, I. & Tsirka, S. E. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin. Ther. Targets 12, 159\u2013170 (2008).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1427_CR74","doi-asserted-by":"publisher","first-page":"01324","DOI":"10.1128\/mSphere.01324-20","volume":"6","author":"AM Horspool","year":"2021","unstructured":"Horspool, A. M. et al. Interplay of antibody and cytokine production reveals CXCL13 as a potential novel biomarker of lethal SARS-CoV-2 infection. Msphere 6, 01324\u201301320 (2021).","journal-title":"Msphere"},{"key":"1427_CR75","doi-asserted-by":"publisher","first-page":"e02287","DOI":"10.1128\/mbio.02287-23","volume":"15","author":"Q Zeng","year":"2024","unstructured":"Zeng, Q. et al. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels. mBio 15, e02287\u201302223 (2024).","journal-title":"mBio"},{"key":"1427_CR76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ygeno.2004.02.003","volume":"84","author":"D Shiokawa","year":"2004","unstructured":"Shiokawa, D., Matsushita, T., Kobayashi, T., Matsumoto, Y. & Tanuma, S. -i Characterization of the human DNAS1L2 gene and the molecular mechanism for its transcriptional activation induced by inflammatory cytokines. Genomics 84, 95\u2013105 (2004).","journal-title":"Genomics"},{"key":"1427_CR77","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1427_CR78","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1427_CR79","doi-asserted-by":"publisher","unstructured":"Williams, C. G. et al. Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication. Cell Rep. 36 https:\/\/doi.org\/10.1016\/j.celrep.2021.109479 (2021).","DOI":"10.1016\/j.celrep.2021.109479"},{"key":"1427_CR80","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s42255-021-00479-4","volume":"3","author":"J Chu","year":"2021","unstructured":"Chu, J. et al. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat. Metab. 3, 1466\u20131475 (2021).","journal-title":"Nat. Metab."},{"key":"1427_CR81","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41392-023-01510-8","volume":"8","author":"P Chen","year":"2023","unstructured":"Chen, P., Wu, M., He, Y., Jiang, B. & He, M.-L. Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection. Signal. Transduct. Target. Ther. 8, 237 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1427_CR82","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk0865","volume":"9","author":"R Li","year":"2024","unstructured":"Li, R. et al. Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosis. Sci. Immunol. 9, eadk0865 (2024).","journal-title":"Sci. Immunol."},{"key":"1427_CR83","doi-asserted-by":"publisher","first-page":"m1966","DOI":"10.1136\/bmj.m1966","volume":"369","author":"CM Petrilli","year":"2020","unstructured":"Petrilli, C. M. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Bmj 369, m1966 (2020).","journal-title":"Bmj"},{"key":"1427_CR84","doi-asserted-by":"publisher","first-page":"773","DOI":"10.7326\/M20-3742","volume":"173","author":"SY Tartof","year":"2020","unstructured":"Tartof, S. Y. et al. Obesity and mortality among patients diagnosed With COVID-19: results from an integrated health care organization. Ann. Intern Med 173, 773\u2013781 (2020).","journal-title":"Ann. Intern Med"},{"key":"1427_CR85","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.orcp.2020.05.009","volume":"14","author":"D Moriconi","year":"2020","unstructured":"Moriconi, D. et al. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. Obes. Res Clin. Pract. 14, 205\u2013209 (2020).","journal-title":"Obes. Res Clin. Pract."},{"key":"1427_CR86","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm9151","volume":"14","author":"GJ Mart\u00ednez-Col\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Col\u00f3n, G. J. et al. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Sci. Transl. Med. 14, eabm9151 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1427_CR87","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","volume":"53","author":"Y-M Kim","year":"2021","unstructured":"Kim, Y.-M. & Shin, E.-C. Type I and III interferon responses in SARS-CoV-2 infection. Exp. Mol. Med. 53, 750\u2013760 (2021).","journal-title":"Exp. Mol. Med."},{"key":"1427_CR88","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","volume":"45","author":"I Ben-Sahra","year":"2017","unstructured":"Ben-Sahra, I. & Manning, B. D. mTORC1 signaling and the metabolic control of cell growth. Curr. Opin. Cell Biol. 45, 72\u201382 (2017).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1427_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22166-4","volume":"12","author":"PJ Mullen","year":"2021","unstructured":"Mullen, P. J. et al. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. Nat. Commun. 12, 1876 (2021).","journal-title":"Nat. Commun."},{"key":"1427_CR90","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-pharmtox-010611-134748","volume":"52","author":"CH Johnson","year":"2012","unstructured":"Johnson, C. H., Patterson, A. D., Idle, J. R. & Gonzalez, F. J. Xenobiotic metabolomics: major impact on the metabolome. Annu Rev. Pharm. Toxicol. 52, 37\u201356 (2012).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"1427_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A. et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).","journal-title":"Mol. Cancer"},{"key":"1427_CR92","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12026-022-09268-x","volume":"70","author":"S Fattahi","year":"2022","unstructured":"Fattahi, S., Khalifehzadeh-Esfahani, Z., Mohammad-Rezaei, M., Mafi, S. & Jafarinia, M. PI3K\/Akt\/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy. Immunol. Res. 70, 269\u2013275 (2022).","journal-title":"Immunol. Res."},{"key":"1427_CR93","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.drudis.2021.11.002","volume":"27","author":"MS Basile","year":"2022","unstructured":"Basile, M. S. et al. The PI3K\/Akt\/mTOR pathway: a potential pharmacological target in COVID-19. Drug Discov. Today 27, 848\u2013856 (2022).","journal-title":"Drug Discov. Today"},{"key":"1427_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2021.09.005","volume":"240","author":"R Abu-Eid","year":"2021","unstructured":"Abu-Eid, R. & Ward, F. J. Targeting the PI3K\/Akt\/mTOR pathway: a therapeutic strategy in COVID-19 patients. Immunol. Lett. 240, 1\u20138 (2021).","journal-title":"Immunol. Lett."},{"key":"1427_CR95","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41392-024-01836-x","volume":"9","author":"HJ Shin","year":"2024","unstructured":"Shin, H. J. et al. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation. Signal Transduct. Target. Ther. 9, 125 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1427_CR96","doi-asserted-by":"publisher","unstructured":"Abu-Farha, M. et al. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21103544 (2020).","DOI":"10.3390\/ijms21103544"},{"key":"1427_CR97","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/ijms25010640","volume":"25","author":"H D\u2019Avila","year":"2024","unstructured":"D\u2019Avila, H. et al. d. Lipid metabolism modulation during SARS-CoV-2 infection: a spotlight on extracellular vesicles and therapeutic prospects. Int. J. Mol. Sci. 25, 640 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1427_CR98","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/314537a0","volume":"314","author":"A Lanzavecchia","year":"1985","unstructured":"Lanzavecchia, A. Antigen-specific interaction between T and B cells. Nature 314, 537\u2013539 (1985).","journal-title":"Nature"},{"key":"1427_CR99","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"1427_CR100","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","volume":"38","author":"A Kaczmarek","year":"2013","unstructured":"Kaczmarek, A., Vandenabeele, P. & Krysko, D. V. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209\u2013223 (2013).","journal-title":"Immunity"},{"key":"1427_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46343-1","volume":"13","author":"S Castro-Pearson","year":"2023","unstructured":"Castro-Pearson, S. et al. Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies. Sci. Rep. 13, 20315 (2023).","journal-title":"Sci. Rep."},{"key":"1427_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026332","volume":"6","author":"S Kraemer","year":"2011","unstructured":"Kraemer, S. et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS ONE 6, e26332 (2011).","journal-title":"PLoS ONE"},{"key":"1427_CR103","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1467-9868.00346","volume":"64","author":"JD Storey","year":"2002","unstructured":"Storey, J. D. A direct approach to false discovery rates. J. R. Stat. Soc. Ser. B (Stat. Methodol. 64, 479\u2013498 (2002).","journal-title":"J. R. Stat. Soc. Ser. B (Stat. Methodol."},{"key":"1427_CR104","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"1427_CR105","doi-asserted-by":"publisher","unstructured":"Khairallah, A. & Sigal, A. SomaScan\u00ae proteomic dataset for Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort https:\/\/doi.org\/10.5281\/zenodo.17551035 (2025).","DOI":"10.5281\/zenodo.17551035"},{"key":"1427_CR106","doi-asserted-by":"publisher","unstructured":"Khairallah, A. & Sigal, A.Analysis scripts and figures source data for Host proteins associated with strong neutralizing SARS-CoV-2 antibody responses in a South African cohort. https:\/\/doi.org\/10.5281\/zenodo.17609054 (2025).","DOI":"10.5281\/zenodo.17609054"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01427-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01427-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01427-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:02:34Z","timestamp":1775754154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01427-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01427-7","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}